Biotech Company Signs Licensing Agreement with State University of New York

Mar 24, 2010

Kyto Biopharma Inc. will have patent rights to several technologies within the university’s patent portfolio

The agreement gives Kyto patent rights to the university’s Transcobalamin (Vitamin B12) Receptor and to group of additional patents that the company has identified as critical to its R&D strategy for cancer treatment. Over the past decade, Kyto Biopharma has provided SUNY with research and development funding, and Dr. Edward Quadros of SUNY Brooklyn has managed the company’s R&D efforts, in addition to Dr. Michael Rosenblum of the MD Anderson Cancer Center (TX). According to the press release, “the company intends to develop its Vitamin B12 receptor based technology and engage a suitable partner to assist with the development and commercialization of a marketable cancer therapeutic.”

↑ Back to TechConnect News™

---